Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40366475/
Real-world data confirm the effectiveness, safety, and prednisone-sparing effect of ravulizumab in patients with gMG, especially in those with thymoma.
This Italian multicenter study confirms ravulizumab’s real-world efficacy, safety, and prednisone-sparing benefit in gMG patients, with notable early improvement in those with thymoma and manageable adverse event profile.
Long-term zilucoplan therapy enabled corticosteroid reduction or discontinuation in 61% and NSIST tapering in 30% of gMG patients by Week 120, while maintaining clinical stability and functional improvement.
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40465294/
In this cohort study of ICI use in NAIDs, patients with MG had frequent and more severe exacerbations, while those with MS had few exacerbations. No obvious differences in survival...
Immune checkpoint inhibitors may exacerbate preexisting neurologic autoimmune disorders. In gMG, exacerbation rates were high with notable severity, urging caution when considering ICIs for these patients. Survival outcomes were unaffected.
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy in thymic epithelial tumors with pleural spread or recurrence: a prospective, single-arm, phase II study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40467556/
Pleural spread or recurrence of thymic epithelial tumors (TETs) is a tricky puzzle in the clinic and there is currently no recognized effective treatment. This trial evaluated the safety and...
S-HITOC showed manageable toxicity and promising survival outcomes for thymic tumors with pleural spread, while also providing effective symptom control in associated generalized myasthenia gravis, supporting its clinical value.
Safe use of contrast media in myasthenia gravis: systematic review and updated European Society of Urogenital Radiology Contrast Media Safety Committee guidelines - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38092951/
It is unclear whether modern contrast media can lead to increased symptoms in myasthenia gravis patients after intravenous administration. * There seems to be a small risk of increased myasthenia...
Most myasthenia gravis patients tolerate contrast media safely. Iodine-based agents may trigger symptom exacerbation within 24 hours in under 5% of cases. Gadolinium-based contrast is considered safe.